Literature DB >> 19373213

Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial.

Brent M Egan1, Jan N Basile, Shakaib U Rehman, Phillip B Davis, Curt H Grob, Jessica Flynn Riehle, Christine A Walters, Daniel T Lackland, Carmen Merali, Jean E Sealey, John H Laragh.   

Abstract

BACKGROUND: Undefined pathophysiologic mechanisms likely contribute to unsuccessful antihypertensive drug therapy. The renin test-guided therapeutic (RTGT) algorithm is based on the concept that, irrespective of current drug treatments, subnormal plasma renin activity (PRA) (<0.65 ng/ml/h) indicates sodium-volume excess "V" hypertension, whereas values >or=0.65 indicate renin-angiotensin vasoconstriction excess "R" hypertension.
METHODS: The RTGT algorithm was applied to treated, uncontrolled hypertensives and compared to clinical hypertension specialists' care (CHSC) without access to PRA. RTGT protocol: "V" patients received natriuretic anti-"V" drugs (diuretics, spironolactone, calcium antagonists, or alpha(1)-blockers) while withdrawing antirenin "R" drugs (converting enzyme inhibitors, angiotensin receptor antagonists, or beta-blockers). Converse strategies were applied to "R" patients. Eighty-four ambulatory hypertensives were randomized and 77 qualified for the intention-to-treat analysis including 38 in RTGT (63.9 +/- 1.8 years; baseline blood pressure (BP) 157.0 +/- 2.6/87.1 +/- 2.0 mm Hg; PRA 5.8 +/- 1.6; 3.1 +/- 0.3 antihypertensive drugs) and 39 in CHSC (58.0 +/- 2.0 years; BP 153.6 +/- 2.3/91.9 +/- 2.0; PRA 4.6 +/- 1.1; 2.7 +/- 0.2 drugs).
RESULTS: BP was controlled in 28/38 (74% (RTGT)) vs. 23/39 (59% (CHSC)), P = 0.17, falling to 127.9 +/- 2.3/73.1 +/- 1.8 vs. 134.0 +/- 2.8/79.8 +/- 1.9 mm Hg, respectively. Systolic BP (SBP) fell more with RTGT (-29.1 +/- 3.2 vs. -19.2 +/- 3.2 mm Hg, P = 0.03), whereas diastolic BP (DBP) declined similarly (P = 0.32). Although final antihypertensive drug numbers were similar (3.1 +/- 0.2 (RTGT) vs. 3.0 +/- 0.3 (CHSC), P = 0.73) in "V" patients, 60% (RTGT) vs. 11% (CHSC) of "R" drugs were withdrawn and BP medications were reduced (-0.5 +/- 0.3 vs. +0.7 +/- 0.3, P = 0.01).
CONCLUSIONS: In treated but uncontrolled hypertension, RTGT improves control and lowers BP equally well or better than CHSC, indicating that RTGT provides a reasonable strategy for correcting treated but uncontrolled hypertension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19373213     DOI: 10.1038/ajh.2009.63

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  38 in total

Review 1.  Diagnosis and treatment of primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; Franco Veglio
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

2.  Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.

Authors:  Stephen T Turner; Gary L Schwartz; Arlene B Chapman; Amber L Beitelshees; John G Gums; Rhonda M Cooper-DeHoff; Eric Boerwinkle; Julie A Johnson; Kent R Bailey
Journal:  Am J Hypertens       Date:  2010-08-19       Impact factor: 2.689

Review 3.  Personalized vascular medicine: individualizing drug therapy.

Authors:  Emil M Degoma; Giovanni Rivera; Scott M Lilly; M Haris U Usman; Emile R Mohler
Journal:  Vasc Med       Date:  2011-10       Impact factor: 3.239

Review 4.  Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention.

Authors:  Samuel J Mann; Michael E Ernst
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

Review 5.  Comparative effectiveness research in the "real" world: lessons learned in a study of treatment-resistant hypertension.

Authors:  Marilyn A Laken; Rosalind Dawson; Otis Engelman; Oscar Lovelace; Charles Way; Brent M Egan
Journal:  J Am Soc Hypertens       Date:  2013 Jan-Feb

Review 6.  Loop Diuretics in the Treatment of Hypertension.

Authors:  Line Malha; Samuel J Mann
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

Review 7.  Individualizing antihypertensive combination therapies: clinical and hemodynamic considerations.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

8.  Physiologic tailoring of treatment in resistant hypertension.

Authors:  J David Spence
Journal:  Curr Cardiol Rev       Date:  2010-05

Review 9.  Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.

Authors:  Francesca Cagnoni; Christian Achiri Ngu Njwe; Augusto Zaninelli; Alessandra Rossi Ricci; Diletta Daffra; Antonio D'Ospina; Paola Preti; Maurizio Destro
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

Review 10.  Rational use of antihypertensive medications in children.

Authors:  Michael A Ferguson; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2013-05-29       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.